HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage

被引:46
|
作者
Pääjärvi, G
Roudier, E
Crisby, M
Högberg, J
Stenius, U
机构
[1] Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden
[2] Karolinska Inst, Neurotec Dept, Div Geriatr Med, Stockholm, Sweden
[3] Karolinska Univ Hosp, Stockholm, Sweden
来源
FASEB JOURNAL | 2004年 / 18卷 / 15期
关键词
pravastatin; 3-hydroxy-3-methyl-glutaryl-CoA;
D O I
10.1096/fj.04-2745fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
3-Hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors, statins, are widely used cholesterol-lowering drugs and have been shown to have anticancer effects in many models. We have investigated the effect of statins on Mdm2, a p53-specific ubiquitin ligase. It was found that pravastatin induced Mdm2 phosphorylation at Ser166 and at 2A10 antibody-specific epitopes in HepG2 cells, while mRNA levels were unchanged. Furthermore, pravastatin was found to induce phosphorylation of mTOR at Ser2448. Ser166 phosphorylation of Mdm2 was abrogated by an inhibitor of mTOR, rapamycin, but not by the PI3-kinase inhibitors LY294002 and wortmannin. Ser166 phosphorylation of Mdm2 has been associated to active Mdm2 and has been shown to increase its ubiquitin ligase activity and lead to increased p53 degradation. Our data show that statins attenuated the p53 response to DNA damage. Thus, in HepG2 cells pravastatin and simvastatin pretreatment attenuated the p53 response to DNA damage induced by 5-fluorouracil and benzo( a) pyrene. Similar attenuation was induced when p53 stabilization was induced by the inhibitor of nuclear export, leptomycin B. Furthermore, in the DNA-damaged cells, half-lives of Mdm2 and p53 were decreased by statins, indicating a more rapid formation of p53/Mdm2 complexes and facilitated p53 degradation. The induction of p53 responsive genes and apoptosis was attenuated. Mdm2 and p53 were also studied in vivo in rat liver employing immunohistochemistry, and it was found that constitutive Mdm2 expression was changed in livers of pravastatin-treated rats. We also show that the p53 response to a challenging dose of diethylnitrosamine was attenuated in hepatocytes in situ and in primary cultures of hepatocytes by pravastatin pretreatment. Taken together, these data indicate that statins induce an mTOR-dependent Ser166 phosphorylation of Mdm2, and this effect may attenuate the duration and intensity of the p53 response to DNA damage in hepatocytes.
引用
收藏
页码:476 / +
页数:23
相关论文
共 50 条
  • [21] HMG-COA reductase inhibitors (statins) increase the expression of COX-2 in gallbladder epithelial cells
    Choi, Min Ho
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A33 - A33
  • [22] Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation
    Kulikov, Roman
    Winter, Markus
    Blattner, Christine
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (39) : 28575 - 28583
  • [23] MDM2 alternative splicing: fine-tuning the p53 damage response
    Jacob, Aishwarya G.
    Singh, Ravi K.
    Bebee, Thomas W.
    Chandler, Dawn S.
    CANCER RESEARCH, 2012, 72
  • [24] Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2
    Yadahalli, Shilpa
    Neira, Jose L.
    Johnson, Christopher M.
    Tan, Yaw Sing
    Rowling, Pamela J. E.
    Chattopadhyay, Anasuya
    Verma, Chandra S.
    Itzhaki, Laura S.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] TCDD activates Mdm2 and attenuates the p53 response to DNA damaging agents
    Pääjärvi, G
    Viluksela, M
    Pohjanvirta, R
    Stenius, U
    Högberg, J
    CARCINOGENESIS, 2005, 26 (01) : 201 - 208
  • [26] Molecular interaction map of the p53 and Mdm2 logic elements, which control the Off-On switch of p53 in response to DNA damage
    Kohn, KW
    Pommier, Y
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 331 (03) : 816 - 827
  • [27] Combination therapy with p53–MDM2 binding inhibitors for malignancies
    Zegao Jin
    Jianfeng Shen
    Jingyao He
    Chunqi Hu
    Medicinal Chemistry Research, 2015, 24 : 1369 - 1379
  • [28] Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels
    Tudhope, Sue
    Zhao, Yan
    Wittner, Anita
    Wilmore, Elaine
    Bertoli, Annalisa
    Adhikari, Santosh
    Harnor, Suzannah J.
    Del Bello, Fabio
    Piergentili, Alessandro
    Lunec, John
    Hardcastle, Ian R.
    Griffin, Roger J.
    Golding, Bernard R.
    Cano, Celine
    Newell, David R.
    Wedge, Stephen R.
    CANCER RESEARCH, 2014, 74 (19)
  • [29] MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation
    Peuget, Sylvain
    Selivanova, Galina
    CANCER DISCOVERY, 2023, 13 (05) : 1043 - 1045
  • [30] HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression
    Chen, Jui-Ching
    Wu, Mei-Lin
    Huang, Kuo-Chin
    Lin, Wan-Wan
    CARDIOVASCULAR RESEARCH, 2008, 80 (01) : 138 - 150